Cow Milk Protein Allergy
8
1
2
2
Key Insights
Highlights
Success Rate
67% trial completion
Treatment Research
13 treatments under study, led by Commercial Ehf
Research Leaders
7 sponsors active, led by Société des Produits Nestlé (SPN)
Related Conditions
Often studied with 6 related conditions
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 72/100
12.5%
1 terminated out of 8 trials
66.7%
-19.9% vs benchmark
0%
0 trials in Phase 3/4
0%
0 of 2 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.6%
Based on 2 completed trials
Clinical Trials (8)
Growth And Safety Outcomes In Infants With Cow´s Milk Protein Allergy (CMPA) Fed A Novel Extensively Hydrolyzed Formula (eHF)
Partially Hydrolysed Whey Based Formula in Differentiation Between Non IgE Gastrointestinal Cow's Milk Protein Allergy and Milk Intolerance
Tolerance and Growth Outcomes of an Extensively Hydrolysed Anti-regurgitation Casein-based Formula in Infants With Cow's Milk Protein Allergy
Effect of a Hydrolyzed Rice Protein-based Formula on Growth, Tolerance, and Health-related Quality of Life in Infants With Cow's Milk Protein Allergy.
Effect of Elimination Diet on Intestinal Mucus Barrier in Infants With Cow's Milk Protein Allergy
CMPA-GO Study: Growth and Safety Outcomes in Infants With CMPA Fed a Novel Extensively Hydrolyzed Formula
Tolerance to Baked Goods in Allergic Children
Impact of Zinc as a New Adjuvant Therapy for Cow Milk Protein Allergy in Children.
Research Network
Common Treatments
- Commercial Ehf2
- New Generation Ehf2
- Test Formula1
- Control Formula1
- Oral Zinc Supplementation1
Active Sponsors
- Société des Produits Nestlé (SPN)3
- Baskent University1
- Fundació Sant Joan de Déu1
- Hospital Sant Joan de Deu1
- Ain Shams University1
Top Investigators
Hôpital Armand Trousseau - APHP
Lactalis
Lactalis
Cairo University
Cairo University
Related Conditions
- Cow Milk Intolerance1
- Fpies1
- Diet Therapy1
- Hen Egg Allergy1
- Immunoglobulin A1